Medical News

RSS

Educational programs, increased physician collaboration can reduce inappropriate CCTA use

Appropriate use of testing is a hot topic in medicine as physicians and hospitals look for ways to improve quality while containing cost to achieve high-value care. This is especially true in the field of cardiology where the potential consequences of incorrect diagnosis have led to overuse of cardiovascular imaging with CT scanners, called coronary CT angiography.

9 Aug 2012

One third of all post-partum women exhibit some symptoms of PTSD

Post-Traumatic Stress Disorder (PTSD) develops in individuals who experience highly traumatizing situations such as terrorist attacks and car accidents, but symptoms can also come about after normal life events - including childbirth.

9 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012

Inaugural event of National Women's Survivors Convention to be held in Nashville

In August 2013, Nashville will be the host city to the National Women's Survivors Convention (NWSC), a first of its kind national event designed to celebrate women cancer survivors.

9 Aug 2012

VA agrees to move forward on CT screening for veterans at high risk for lung cancer

Today, Lung Cancer Alliance (LCA) announced that the Department of Veterans Affairs (VA) has agreed to move forward on CT screening for veterans at high risk for lung cancer. This was communicated to Laurie Fenton Ambrose, LCA President & CEO in written correspondence by VA Under Secretary for Health Dr. Robert A. Petzel.

9 Aug 2012

AbilTo, Aetna announce new program to help members with diabetes combat depression

The combination of depression and diabetes is common and potentially dangerous. People with depression can find it hard to make the lifestyle changes needed to manage diabetes. If not well managed, diabetes often leads to additional health issues, like heart, circulatory and kidney disease. Today, Aetna and AbilTo are announcing a new program to help members with diabetes combat depression and take control of their diabetes.

9 Aug 2012

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

9 Aug 2012

PAREXEL board approves stock repurchase program

PAREXEL International Corporation announced today that its Board of Directors has approved a stock repurchase program authorizing the repurchase of up to $200 million of the Company's common stock, subject to the consent of the Company's lenders.

From Parexel 9 Aug 2012

Cardionovum to introduce PROLIMUS Biograde system in Europe

Cardionovum GmbH announced today that it expects to launch in Europe in Q4 2012 a next-generation Sirolimus-eluting coronary stent system—PROLIMUS Biograde—which is designed to optimize long-term patient results. Unlike many state-of-the-art DES that are currently being marketed, PROLIMUS Biograde provides multiple pro-healing product features to promote early re-endothelialization.

9 Aug 2012

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

FDA approves Codman’s MEDSTREAM Programmable Infusion System

Codman & Shurtleff, Inc. (Codman), the global neurological device company, has received U.S. Food and Drug Administration (FDA) approval through a PMA supplement for its MEDSTREAM Programmable Infusion System, an implantable infusion pump and catheter system used in the treatment of spasticity, a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury.

9 Aug 2012

Roundup: Seeking medical malpractice alternatives part of Mass. cost control law; Low-Income Health Program signs up 400k in Calif.

It may not seem like big news, but if you've followed the long-running, stubborn and mostly dug-in debate over reforming medical malpractice in the U.S., you know that when doctors and lawyers issue a joint news release, something is really going on. ... Formally, it's called "Disclosure, Apology and Offer" and it's a key provision of the new state health cost law. Massachusetts doctors and lawyers have agreed to work side by side on this less hostile (and potentially cost-saving) approach to dealing with medical errors and malpractice.

9 Aug 2012